Phase 1RecruitingPriority 4 · Lower priorityNCT04771572
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Plain-language summary
This trial is testing LP-118 for patients with T-cell prolymphocytic leukemia (T-PLL) who have been newly diagnosed and have not yet received treatment as well as those whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. This trial is available at 8 locations in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 13 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
LP-118 (DRUG): novel, oral, selective treatment for hematological malignancies tested through ascending dose levels
LP-118
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details